title: Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis.
abstract: Detection and quantification of different Pneumocystis carinii (PC) life cycle forms were performed by polymerase chain reaction (PCR) and by morphological stains on bronchoalveolar lavage fluids (BALF) from HIV-infected patients with P. carinii pneumonia (PCP). The number of PC trophozoites was higher in patients with PCP who were receiving prophylaxis than in those not receiving prophylaxis. Also the cyst: trophozoite ratio was lower in the first group. No difference was observed between patients receiving different prophylactic medications. The imbalance between PC forms in BALF from patients with PCP receiving anti-PC prophylaxis may hamper the sensitivity of cyst stains. Multiple stains or PCR examination should be performed on BALF from patients with clinically suspected PCP who are receiving prophylaxis.
authors.affiliation: Department of Infectious Diseases, Università Cattolica S. Cuore, Rome, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Tamburrini
authors.forename: P
authors.initials: P
authors.lastname: Mencarini
authors.forename: E
authors.initials: E
authors.lastname: Visconti
authors.forename: A
authors.initials: A
authors.lastname: De Luca
authors.forename: M
authors.initials: M
authors.lastname: Zolfo
authors.forename: A
authors.initials: A
authors.lastname: Siracusano
authors.forename: E
authors.initials: E
authors.lastname: Ortona
authors.forename: R
authors.initials: R
authors.lastname: Murri
authors.forename: A
authors.initials: A
authors.lastname: Antinori
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000382:microbiology* / Q000517:prevention & control; D000328:Adult; D000890:Anti-Infective Agents; D000935:Antifungal Agents / Q000627:therapeutic use; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology*; D004271:DNA, Fungal / Q000032:analysis; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010419:Pentamidine / Q000627:therapeutic use; D011010:Pneumocystis / Q000235:genetics / Q000254:growth & development*; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis / Q000382:microbiology* / Q000517:prevention & control; D016133:Polymerase Chain Reaction; D011739:Pyrimethamine / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D000935:Antifungal Agents; D004271:DNA, Fungal; D010419:Pentamidine; D003622:Dapsone; D011739:Pyrimethamine